



Special Import Permit Use

PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets) is under special import permit by the Instituto para a Supervisão e Administração Farmacêutica do Governo da Região Administrativa Especial de Macau for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.

Healthcare Professionals can refer to the “FACT SHEET FOR HEALTHCARE PROVIDERS: EMERGENCY USE AUTHORIZATION FOR PAXLOVID™” and “FACT SHEET FOR PATIENTS, PARENTS, AND CAREGIVERS” on the PAXLOVID™ product information (United States) page:

[US FACT SHEET FOR HEALTHCARE PROVIDERS: EMERGENCY USE AUTHORIZATION FOR PAXLOVID™](#)

[US FACT SHEET FOR PATIENTS, PARENTS, AND CAREGIVERS” on the PAXLOVID™](#)

For reference only, “PAXLOVID™ Patient Information Leaflet” in Chinese can be accessed below. Please refer to the US “FACT SHEET FOR PATIENTS, PARENTS, AND CAREGIVERS” for the latest information. Variations are presence against the US “FACT SHEET FOR PATIENTS, PARENTS, AND CAREGIVERS”:

[PAXLOVID™ Patient Information Leaflet \(Chinese\)](#)